CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
CytoDyn (OTCQB: CYDY) has appointed Robert E. Hoffman as its new Chief Financial Officer, effective May 15, 2025. Hoffman, a seasoned biotech veteran, will replace interim CFO Mitch Cohen. With extensive experience in financial leadership, Hoffman previously served as President, CEO, interim CFO, and Chairperson at Kintara Therapeutics, and held CFO positions at companies including Heron Therapeutics, Innovus Pharmaceuticals, and AnaptysBio.
Hoffman currently serves on the boards of several companies, including Esperion Therapeutics, TuHURA Biosciences, and Fibrobiologics. His appointment aims to support CytoDyn's clinical development pipeline, particularly in oncology indications. The company is developing leronlimab, a CCR5 antagonist with potential for multiple therapeutic applications.
CytoDyn (OTCQB: CYDY) ha nominato Robert E. Hoffman come nuovo Chief Financial Officer, a partire dal 15 maggio 2025. Hoffman, veterano esperto del settore biotech, sostituirà l'amministratore delegato ad interim Mitch Cohen. Con una vasta esperienza nella leadership finanziaria, Hoffman ha ricoperto in precedenza ruoli di Presidente, CEO, CFO ad interim e Presidente del consiglio di amministrazione presso Kintara Therapeutics, oltre a posizioni di CFO in aziende come Heron Therapeutics, Innovus Pharmaceuticals e AnaptysBio.
Attualmente Hoffman fa parte dei consigli di amministrazione di diverse società, tra cui Esperion Therapeutics, TuHURA Biosciences e Fibrobiologics. La sua nomina mira a supportare il pipeline di sviluppo clinico di CytoDyn, in particolare nelle indicazioni oncologiche. L'azienda sta sviluppando leronlimab, un antagonista CCR5 con potenziali applicazioni terapeutiche multiple.
CytoDyn (OTCQB: CYDY) ha designado a Robert E. Hoffman como su nuevo Director Financiero, con efecto a partir del 15 de mayo de 2025. Hoffman, un veterano experimentado en biotecnología, reemplazará al director financiero interino Mitch Cohen. Con amplia experiencia en liderazgo financiero, Hoffman ha ocupado anteriormente cargos como Presidente, CEO, director financiero interino y presidente en Kintara Therapeutics, además de desempeñarse como CFO en empresas como Heron Therapeutics, Innovus Pharmaceuticals y AnaptysBio.
Actualmente, Hoffman forma parte de los consejos de administración de varias compañías, incluyendo Esperion Therapeutics, TuHURA Biosciences y Fibrobiologics. Su nombramiento busca apoyar la cartera de desarrollo clínico de CytoDyn, especialmente en indicaciones oncológicas. La compañía está desarrollando leronlimab, un antagonista CCR5 con potencial para múltiples aplicaciones terapéuticas.
CytoDyn (OTCQB: CYDY)는 2025년 5월 15일부로 Robert E. Hoffman을 새로운 최고재무책임자(CFO)로 임명했습니다. 바이오테크 분야의 베테랑인 Hoffman은 임시 CFO인 Mitch Cohen을 대체할 예정입니다. 풍부한 재무 리더십 경험을 가진 Hoffman은 이전에 Kintara Therapeutics에서 사장, CEO, 임시 CFO, 이사회 의장으로 근무했으며, Heron Therapeutics, Innovus Pharmaceuticals, AnaptysBio 등 여러 회사에서 CFO를 역임했습니다.
현재 Hoffman은 Esperion Therapeutics, TuHURA Biosciences, Fibrobiologics 등 여러 회사의 이사회에 참여하고 있습니다. 그의 임명은 특히 암 치료 적응증 분야에서 CytoDyn의 임상 개발 파이프라인을 지원하기 위한 것입니다. 회사는 여러 치료 응용 가능성을 가진 CCR5 길항제인 leronlimab을 개발 중입니다.
CytoDyn (OTCQB : CYDY) a nommé Robert E. Hoffman en tant que nouveau Directeur Financier, à compter du 15 mai 2025. Hoffman, vétéran expérimenté du secteur biotechnologique, remplacera le CFO par intérim Mitch Cohen. Fort d'une vaste expérience en gestion financière, Hoffman a précédemment occupé les postes de Président, CEO, CFO par intérim et Président du conseil d'administration chez Kintara Therapeutics, ainsi que des fonctions de CFO dans des entreprises telles que Heron Therapeutics, Innovus Pharmaceuticals et AnaptysBio.
Hoffman siège actuellement aux conseils d'administration de plusieurs sociétés, dont Esperion Therapeutics, TuHURA Biosciences et Fibrobiologics. Sa nomination vise à soutenir le pipeline de développement clinique de CytoDyn, notamment dans les indications en oncologie. La société développe le leronlimab, un antagoniste CCR5 avec un potentiel pour de multiples applications thérapeutiques.
CytoDyn (OTCQB: CYDY) hat Robert E. Hoffman mit Wirkung zum 15. Mai 2025 zum neuen Chief Financial Officer ernannt. Hoffman, ein erfahrener Biotech-Veteran, wird den interimistischen CFO Mitch Cohen ablösen. Mit umfangreicher Erfahrung in der Finanzführung war Hoffman zuvor Präsident, CEO, interimistischer CFO und Vorsitzender bei Kintara Therapeutics und bekleidete CFO-Positionen bei Unternehmen wie Heron Therapeutics, Innovus Pharmaceuticals und AnaptysBio.
Derzeit sitzt Hoffman in den Aufsichtsräten mehrerer Unternehmen, darunter Esperion Therapeutics, TuHURA Biosciences und Fibrobiologics. Seine Ernennung soll die klinische Entwicklungspipeline von CytoDyn unterstützen, insbesondere bei onkologischen Indikationen. Das Unternehmen entwickelt leronlimab, einen CCR5-Antagonisten mit Potenzial für vielfältige therapeutische Anwendungen.
- Appointment of experienced biotech veteran with extensive financial leadership background
- New CFO brings significant board experience and industry connections
- Strategic timing coincides with company's focus on advancing clinical development pipeline
- Trading on OTCQB market indicates lower tier listing status
- Frequent management changes with interim CFO serving only since February 2024
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E. Hoffman has been appointed as Chief Financial Officer, effective May 15, 2025. He will take over the CFO position from Mitch Cohen, who had been serving as CFO on an interim basis since February 2024.
Mr. Hoffman is an industry veteran with decades of financial and leadership experience, having served in a number of biotech executive and board roles. Most recently, he was the President, CEO, interim Chief Financial Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. Prior to that, he served as Chief Financial Officer and Senior Vice President of Heron Therapeutics, Inc., Chief Financial Officer and Executive Vice President of Innovus Pharmaceuticals, Inc. and Chief Financial Officer of AnaptysBio, Inc. Mr. Hoffman started his career at Arena Pharmaceuticals, Inc., rising through the ranks to Senior Vice President, Finance and Chief Financial Officer. Mr. Hoffman currently serves on the board of directors of Esperion Therapeutics, Inc., TuHURA Biosciences and Fibrobiologics, Inc., and has previously served as a director of several public and private life sciences companies, including ASLAN Pharmaceuticals Limited, Saniona AB, Kura Oncology, Inc., CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Aravive, Inc.
Mr. Hoffman is a former member of the steering committee of the Association of Bioscience Financial Officers. He also formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standards Board from 2010 to 2020. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.
“We are pleased to welcome Robert to the CytoDyn team at such an exciting moment for the Company. Robert brings critical financial and capital markets expertise, and extensive experience in the life sciences sector. As part of the senior leadership team, Robert will help support CytoDyn’s efforts to advance our clinical development pipeline, with a special focus on our promising recent discoveries in the oncology indication,” said Dr. Jacob Lalezari, CEO of CytoDyn. “I would also like to thank Mitch for all his contributions to CytoDyn. It has been a pleasure to work together, and we wish him all the best in the future.”
Mr. Hoffman will work with Mr. Cohen to facilitate a smooth transition over the next several weeks.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Media Contacts
CytoDyn Inc.
Riyaz Lalani
Gagnier Communications
CytoDyn@gagnierfc.com
FAQ
Who is the new CFO of CytoDyn (CYDY) and when does he start?
What is Robert Hoffman's previous experience before joining CytoDyn as CFO?
What companies is Robert Hoffman currently serving as board member?
What is CytoDyn's main product in development?
